首页> 外国专利> NOR-1 AND NUR77 NUCLEAR RECEPTORS AS TARGETS FOR ANTI-LEUKEMIA THERAPY

NOR-1 AND NUR77 NUCLEAR RECEPTORS AS TARGETS FOR ANTI-LEUKEMIA THERAPY

机译:NOR-1和NUR77核受体作为抗白血病治疗的靶标

摘要

The present invention is directed to the application of nuclear receptor transcription factors as molecular targets for therapeutic intervention in the treatment of myeloid leukemia. More specifically, nor-1 and nur77 nuclear receptors are targets for myeloid leukemia therapy. The figure shows the growth curve of one litter including two nor-1KO/nur77KO mice and their normal littermates that is representative of a number of litters that were weighed daily for a period of two weeks.
机译:本发明涉及核受体转录因子作为分子靶标在骨髓性白血病治疗中的治疗干预的应用。更具体地说,nor-1和nur77核受体是骨髓性白血病治疗的靶标。该图显示了一只窝的生长曲线,其中包括两只nor-1KO / nur77KO小鼠及其正常同窝仔,代表了每天要称重两周的多个窝。

著录项

  • 公开/公告号AU2003230947A1

    专利类型

  • 公开/公告日2003-11-03

    原文格式PDF

  • 申请/专利权人 BAYLOR COLLEGE OF MEDECINE;

    申请/专利号AU20030230947

  • 申请日2003-04-15

  • 分类号A01N37/18;A61Bnull/null;A61K31/70;A61K38/00;A61K48/00;C12N5/00;C12N15/00;C12N15/63;C12N15/861;

  • 国家 AU

  • 入库时间 2022-08-21 23:56:46

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号